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inhaled formulations of anti-asthma drugs to direct them to 
the site of action, many pharmaceutical companies have 
elected to develop the initial anti-leukotriene drugs as oral 
formulations, presumably because of patient preference 
with this route of administration in the large U.S. and 
Japanese markets. The availability of this new class of 
anti-leukotriene drugs should prompt the pharmaceutical 
industry to escalate its efforts to discover topically active 
corticosteroids which have minimal systemic effect, either 
by intensified endeavours in medicinal chemistry or by 
some alteration to the pharmaceutical formulation such 
that the effects of the inhaled drug are confined to the lung. 
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Reply to Drs Seale and Donnelly 
Drs Seale and Donnelly make several important points 
regarding the challenge inhaled glucocorticoids now face 
with the introduction of leukotriene modifiers (1). How- 
ever, it is the opinion leaders who are at the crossroads and 
face the challenge in defining the appropriate management 
for asthma. In recent years, opinion leader teams or 
‘expert panels’ have profiled inhaled glucocorticoids as the 
‘preferred’ long-term asthma control medication (2,3). 
Numerous studies show that inhaled glucocorticoids 
improve overall asthma management, reduce the need for 
rescue bronchodilator therapy, and reduce hospitalizations 
(4-7). They also improve pulmonary function and reduce 
airways hyperresponsiveness with long-term treatment 
(4-5). Recent observations suggest that the response to 
inhaled glucocorticoids is highly dependent on the time of 
intervention, the earlier used the better (5,7-9). These 
observations have raised the question whether delays in 
intervention, specifically with inhaled glucocorticoids, lead 
to irreversible or incompletely reversible changes in airway 
pathology. 
The inhaled glucocorticoids as a class, however, face a 
formidable challenge to retain their position as the pre- 
ferred medication for long-term asthma control. Their 
effect is limited to the duration of treatment (5), they do not 
induce remission, and the response to glucocorticoids can 
vary among patients (10). In addition, recent reports have 
raised concern regarding the risk of adverse effects with 
long-term high-dose inhaled glucocorticoid therapy (11,lZ). 
Attempts to compare the various inhaled glucocorticoids 
have placed emphasis on measures of cortisol suppression 
and have consequently drawn attention to the systemic 
effects of all inhaled glucocorticoids. Indeed, Seale and 
Donnelly’s report utilizes cortisol suppression to derive 
potency ratios for the systemic effect of two inhaled gluco- 
corticoids (1). Unfortunately, this type of information has 
not defined a ‘preferred’ inhaled glucocorticoid. It appears 
that as the potency of an inhaled glucocorticoid increases in 
relation to efficacy, there appears to be a corresponding 
increase in potency on cortisol suppression. Putting the two 
measures together, that is, efficacy and systemic effect 
potency, could lead to the development of a therapeutic 
index. Attempts to define this therapeutic index have not 
been successful, but studies are now in progress under the 
direction of the National Heart, Lung and Blood Institute 
Asthma Clinical Research Network. 
Other medications described as ‘controllers’ prevent 
symptoms and improve pulmonary function, but do no 
resolve airways inflammation, for example long-acting 
b-agonists. Interest has grown in the leukotriene modifier 
class of long-term asthma controllers. In the U.S.A., three 
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leukotriene modifiers are now available, a leukotriene 
synthesis inhibitor, zileuton, and two leukotriene 
antagonists, zafirlukast and montelukast. Montelukast is 
particularly attractive among the leukotriene modifiers 
since it can be administered once daily, has a very good 
safety profile, no reported drug interactions, and no special 
requirements for administration in relation to meals. It has 
also been profiled for use in children as young as 6 years of 
age. 
Given the favourable safety profile of the newer leuko- 
triene modifiers, should they now become the ‘preferred’ 
long-term asthma control medication? At this time, it seems 
premature to follow that direction. First of all, the clinical 
experience with leukotriene modifiers is only a few years 
with very limited patient exposure. Second, inhaled gluco- 
corticoids have demonstrated effects on reducing airway 
inflammation including a reduction in collagen and tenascin 
deposition (13-21). The latter observation suggests that 
inhaled glucocorticoids have unique effects on airway 
remodelling. Other long-term control medications, includ- 
ing leukotriene modifiers, have not shown comparable 
effects on resolution of airway inflammation. 
Studies are now needed to compare the long-term effects 
of both classes of controller medications, inhaled gluco- 
corticoids and leukotriene modifiers, with the ‘preferred’ 
medication of each class. These studies should examine the 
relative effects of these medications on pulmonary function 
as well as resolution of airway inflammation including the 
proposed irreversible or incompletely reversible changes. 
Long-term safety studies are also necessary to determine the 
relative efficacy and safety of these medications, especially 
for early intervention and long-term asthma management 
for children. These studies are critical in defining the future 
course of asthma therapy. 
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Reply to Drs Seale and Donnelly 
The study by Drs Seale and Donnelly confirms previous 
dose-response studies in healthy adults showing a more 
potent systemic activity of fluticasone propionate (FP) than 
that of budesonide (BUD) when delivered from comparable 
devices (l-3). Paediatric data on asthmatic children may be 
interpreted in support of this difference in systemic potency. 
FP exhibited a greater systemic bioactivity than BUD as 
evaluated from free cortisol in 12-h night urine from 
school-children after single doses of FP and BUD delivered 
from comparable devices (4). FP and BUD had similar 
systemic potency in school-children when delivered regu- 
larly from the Diskus and Turbuhaler devices, respectively. 
Free cortisol in diurnal urine and short-term knemometry 
was used as outcome (5). In young children of age l-3 
years, knemometry showed similar systemic activity from 
FP inhaled via the Babyhaler device and BUD inhaled via a 
metalspacer (6). In the latter two paediatric studies, the 
device used to deliver BUD would be expected to provide a 
higher lung dose than the device used to deliver FP (7). 
Since lung dose is the major determinant of systemic 
activity, such data are compatible with adult data showing 
that the FP molecule causes more potent systemic activity 
than the BUD molecule, bearing in mind the important 
effect of the delivery device on systemic bioactivity. 
Together, these data provide very important information 
on the systemic activity of FP in contrast to previous 
claims that FP was without systemic activity within the 
recommended therapeutic dose-range. 
However disappointing as this may be, it should not 
discourage the continued use of inhaled steroids, including 
FP. It is important to emphasize that the documented 
systemic activity is not synonymous of clinical side-effects. 
Clinical side-effects can only be measured by clinically 
relevant outcomes. 
The measurement of systemic activity provides useful 
information about the relative systemic potency of various 
steroid treatments including steroid and delivery devices. 
With proper use of comparative data on efficacy this can 
provide information about the therapeutic index and the 
safer treatment regime. Systemic activity may be measured 
indirectly in numerous ways, including the integration of 
diurnal adrenal function as reflected in plasma or urine, 
measures of bone and connective tissue turn-over, short- 
term growth in children by knemometry and others. How- 
ever, these measures only become clinically relevant if the 
capacity of the adrenal gland to respond adequately to 
stress is impaired, if there is an adverse effect on bone 
formation or statural height velocity, or if other clinically 
relevant outcomes are affected. 
Measures of systemic activity vary in their sensitivity. 
In paediatrics the development has provided increasingly 
sensitive measures of systemic activity, which has revealed 
systemic activity from increasingly lower doses. Doses 
below 16OOpg BUD were considered without apparent 
systemic activity a decade ago, when morning p-cortisol 
was considered state-of-the-art for such a purpose. When 
the use of free cortisol in 24-h urine was adopted, doses of 
c. 8OOpg BUD showed systemic activity (8). The subse- 
quent introduction of knemometry for measurements of 
systemic activity identified activity in doses of 400 pg BUD 
(9). Improved methods will certainly identify systemic 
activity in even lower doses in the future. Obviously, this 
does not mean that the safe dose is becoming equally 
diminished. 
In conclusion, systemic activity should only be used for 
comparisons between various steroid regimes, while safety 
should be studied by clinical outcome. Any consideration as 
to the safety of treatment should, therefore, be restricted to 
clinical outcome. 
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